5-Amino-1MQ: What It Is and Whether It Actually Works

Short answer: 5-Amino-1MQ is a selective NNMT inhibitor with consistently positive mouse data on fat mass, cholesterol, and metabolic markers — but published human clinical trials aren't available yet, and it is not FDA-approved for any indication.

5-Amino-1MQ is one of the more mechanistically novel compounds in the longevity space, backed by a genuinely consistent body of animal research. Unlike many repurposed drugs in this category, it was developed specifically to target a single, well-defined metabolic pathway — and the preclinical results across multiple independent studies point in the same direction. Here's what the science actually shows.

What 5-Amino-1MQ Actually Is

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable, selective inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme highly expressed in white adipose tissue, liver, and skeletal muscle.^[1]

NNMT works by transferring a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing a byproduct called 1-methylnicotinamide. This reaction consumes SAM — the body's primary methyl donor — and diverts nicotinamide away from the NAD+ salvage pathway.^[1] Because NNMT expression increases in obesity and insulin resistance, researchers proposed that inhibiting it could preserve SAM levels, restore nicotinamide availability for NAD+ synthesis, and improve cellular energy metabolism^[1] — a genuinely elegant hypothesis, purpose-built around this specific pathway rather than a repurposed mechanism borrowed from another use case.

The Foundational Mouse Study

In 2018, researchers at the University of Texas Medical Branch and University of Texas at San Antonio published the foundational pharmacology study characterizing 5-Amino-1MQ, establishing it as a selective NNMT inhibitor.^[1] The results were notable: diet-induced obese mice treated with 5-Amino-1MQ for just 11 days lost approximately 5.1% of their body weight from baseline — versus a 1.4% weight gain in control mice — with roughly 35% less white adipose tissue mass and about 30% lower plasma cholesterol. Importantly, this happened without any change in food intake, suggesting a genuine metabolic effect rather than simple appetite suppression.^[1]

What Follow-Up Research Has Confirmed

The encouraging part of 5-Amino-1MQ's story is how consistently the follow-up research has supported the original findings. Subsequent preclinical work confirmed that NNMT inhibition increases intracellular NAD+ and SAM concentrations in adipocytes and suppresses fat-synthesis pathways, exactly as the original mechanism predicted.^[2] A more recent 2024 preclinical study extended the findings further, showing 5-Amino-1MQ treatment in obese mice improved glucose tolerance and insulin sensitivity and reduced liver fat accumulation and inflammation — meaningful metabolic benefits beyond just weight change.^[2]

A separate 2022 study found that combining 5-Amino-1MQ with a reduced-calorie diet produced faster normalization of body weight and adiposity than diet change alone, along with distinct, favorable shifts in gut microbiome composition.^[3] Across every published study to date, the direction of the findings has been consistent — a genuinely reassuring pattern in preclinical research, where results often conflict from study to study.

Where the Research Currently Stands

The one honest gap worth naming: all of this evidence comes from cell culture and mouse models. Human clinical trial data for 5-Amino-1MQ hasn't been published yet — which puts it earlier in the research pipeline than compounds like metformin or rapamycin that already carry decades of human safety data from other approved uses. That's simply where a genuinely novel compound with a purpose-built mechanism starts: strong, consistent preclinical signal, with human trials as the natural next step rather than something that's already happened.

Regulatory Status

5-Amino-1MQ is not yet FDA-approved for any indication in humans, and it's not currently included on the FDA's 503B "Bulks List" — the list of substances compounding outsourcing facilities can use under certain regulatory exemptions based on a determined clinical need. That reflects where the compound sits in the regulatory pipeline more than a judgment on the science itself.

Comparing providers? See5-Amino-1MQ and related Longevity catalog pricingon RENVA's Longevity hub.

The Bottom Line

5-Amino-1MQ has one of the more scientifically coherent stories in the longevity space: a specific, well-understood enzyme target, a purpose-built inhibitor, and consistently positive results across multiple independent animal studies. What it doesn't have yet is published human trial data — which is worth knowing not as a red flag, but as an accurate picture of where this compound sits in its research timeline. It's a genuinely promising candidate that's ahead of the curve mechanistically and still waiting on the human studies to catch up.

Frequently Asked Questions